Nautilus Biotechnology, Inc.
General ticker "NAUT" information:
- Sector: Health Care
- Industry: Life Sciences Tools & Services
- Capitalization: $144.2M (TTM average)
Nautilus Biotechnology, Inc. follows the US Stock Market performance with the rate: 24.0%.
Estimated limits based on current volatility of 5.5%: low 1.90$, high 2.13$
Factors to consider:
- Total employees count: 155 (-7.2%) as of 2024
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Dependence on proteomics platform, High R&D costs, Market competition, Third-party risks, Geopolitical risks
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.25$, 3.01$]
- 2025-12-31 to 2026-12-31 estimated range: [1.12$, 2.70$]
Financial Metrics affecting the NAUT estimates:
- Positive: with PPE of -3.1 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -27.12 <= 0.33
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Investing cash flow per share per price, % of 30.38 > -0.66
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Shareholder equity ratio, % of 85.99 > 63.39
Short-term NAUT quotes
Long-term NAUT plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $63.62MM | $76.15MM | $81.48MM |
| Operating Income | $-63.62MM | $-76.15MM | $-81.48MM |
| Non-Operating Income | $5.69MM | $12.48MM | $10.70MM |
| Interest Expense | $5.82MM | $0.00MM | $0.00MM |
| R&D Expense | $36.45MM | $47.25MM | $50.48MM |
| Income(Loss) | $-57.92MM | $-63.67MM | $-70.78MM |
| Profit(Loss)* | $-57.92MM | $-63.67MM | $-70.78MM |
| Stockholders Equity | $314.92MM | $265.35MM | $208.73MM |
| Assets | $350.05MM | $305.56MM | $242.74MM |
| Operating Cash Flow | $-45.81MM | $-51.71MM | $-59.15MM |
| Capital expenditure | $2.32MM | $2.44MM | $2.12MM |
| Investing Cash Flow | $-25.74MM | $-43.73MM | $66.25MM |
| Financing Cash Flow | $0.56MM | $0.37MM | $1.14MM |
| Earnings Per Share** | $-0.46 | $-0.51 | $-0.56 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.